. 2016 Apr 30;2016:4851935. doi: 10.1155/2016/4851935

(d).

Variable	Group	RTE (CI)
Variable	Group	Pre	Post	3 h
B2M	EET	0.48 (0.39; 0.57)	0.82 (0.75; 0.86)^∗∗∗	0.60 (0.51; 0.69)^∗
B2M	SED^§/$$$	0.26 (0.20; 0.34)^$	0.42 (0.34; 0.52)^∗∗/$$$	0.37 (0.29; 0.46)^$

CA-19-9	EET	0.44 (0.34; 0.55)	0.52 (0.42; 0.62)	0.54 (0.45; 0.63)
CA-19-9	SED^§	0.52 (0.41; 0.63)	0.52 (0.42; 0.62)	0.46 (0.36; 0.57)

CEA	EET	0.47 (0.38; 0.57)	0.67 (0.58; 0.74)^∗∗∗	0.48 (0.38; 0.58)
CEA	SED^§	0.42 (0.32; 0.53)	0.49 (0.39; 0.6)	0.45 (0.35; 0.56)

CK-MB	EET	0.54 (0.45; 0.62)	0.69 (0.6; 0.75)^∗∗	0.74 (0.69; 0.79)^∗∗∗
CK-MB	SED^§/$$$	0.27 (0.21; 0.35)^$$	0.27 (0.20; 0.36)^$$$	0.44 (0.35; 0.53)^∗∗/$$

FABP, heart	EET	0.27 (0.2; 0.36)	0.67 (0.59; 0.73)^∗∗∗	0.68 (0.6; 0.75)^∗∗∗
FABP, heart	SED^§	0.25 (0.19; 0.34)	0.44 (0.36; 0.54)^∗∗∗/$	0.67 (0.54; 0.77)^∗∗∗

IL-6	EET	0.26 (0.2; 0.34)	0.81 (0.74; 0.85)^∗∗∗	0.44 (0.34; 0.54)^∗
IL-6	SED^§	0.36 (0.26; 0.48)	0.64 (0.54; 0.73)^∗∗∗	0.50 (0.39; 0.61)

MMP-2	EET	0.52 (0.42; 0.61)	0.73 (0.65; 0.79)^∗∗∗	0.61 (0.52; 0.69)^∗
MMP-2	SED^§§/$$	0.35 (0.27; 0.43)	0.38 (0.30; 0.49)^$$	0.37 (0.29; 0.46)^$

MMP-3	EET	0.39 (0.31; 0.48)	0.81 (0.73; 0.86)^∗∗∗	0.49 (0.40; 0.58)^∗∗
MMP-3	SED^§§	0.33 (0.26; 0.41)	0.57 (0.47; 0.66)^∗∗∗/$	0.39 (0.3; 0.50)

PSA-f	EET	0.52 (0.42; 0.61)	0.66 (0.55; 0.74)^∗∗	0.50 (0.41; 0.59)^∗∗
PSA-f	SED^§	0.43 (0.34; 0.53)	0.46 (0.37; 0.56)	0.40 (0.31; 0.51)

B2M = Beta 2 Microglobulin; CA-19-9 = Cancer Antigen 19-9; CEA = Carcinoembryonic Antigen; CK-MB = creatine kinase MB; FABP, heart = fatty acid-binding protein, heart; IL-6 = interleukin-6; MMP-2 = matrix metalloproteinase-2; PSA-f = Prostate Specific Antigen.